Monte Rosa Therapeutics, INC Form 4 insider transactions

Director Kimberly Blackwell acquired stock options for 22,100 shares of Monte Rosa Therapeutics, Inc. (GLUE) on June 12, 2024.

Edmund Dunn, Principal Accounting Officer of Monte Rosa Therapeutics, sold 1,207 shares of common stock on June 3, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Philip Nickson, Chief Business & Legal Officer of Monte Rosa Therapeutics, acquired 40,000 stock options on June 3, 2024, at an exercise price of $3.98.

Sharon Townson, Chief Scientific Officer of Monte Rosa Therapeutics, was granted stock options for 40,000 shares on June 3, 2024.

Jennifer Champoux, Chief Operating Officer of Monte Rosa Therapeutics, acquired 40,000 stock options on June 3, 2024, at an exercise price of $3.98.